Hologic - HOLX Stock Forecast, Price & News

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Hologic Trading Down 0.3 %

Shares of NASDAQ:HOLX traded down $0.24 during trading on Friday, reaching $71.34. 39,679 shares of the company traded hands, compared to its average volume of 1,465,018. The firm has a market capitalization of $17.81 billion, a price-to-earnings ratio of 12.07, a P/E/G ratio of 0.81 and a beta of 1.05. Hologic has a 52-week low of $66.58 and a 52-week high of $81.04. The company has a current ratio of 3.91, a quick ratio of 3.32 and a debt-to-equity ratio of 0.57. The business's fifty day moving average is $70.57 and its 200-day moving average is $72.95.

Hologic (NASDAQ:HOLX - Get Rating) last released its quarterly earnings data on Wednesday, July 27th. The medical equipment provider reported $0.95 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.26. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $896.71 million. Hologic had a return on equity of 37.48% and a net margin of 28.93%. The business's quarterly revenue was down 14.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.33 earnings per share. As a group, analysts forecast that Hologic will post 5.82 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on HOLX. Morgan Stanley lowered their price target on shares of Hologic from $72.00 to $70.00 and set an "equal weight" rating on the stock in a report on Thursday, July 28th. BTIG Research cut shares of Hologic from a "buy" rating to a "neutral" rating in a research report on Monday, July 18th. SVB Leerink upped their price objective on shares of Hologic to $85.00 and gave the stock an "outperform" rating in a research report on Tuesday, May 17th. UBS Group assumed coverage on shares of Hologic in a research report on Wednesday, July 20th. They issued a "neutral" rating and a $73.00 price objective on the stock. Finally, Citigroup decreased their price objective on shares of Hologic from $78.00 to $75.00 in a research report on Thursday, April 28th. Seven investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Hologic currently has a consensus rating of "Hold" and an average price target of $76.71.